


high-risk for HIV. Although this program is sustainable, efforts to improve steps along the PrEP care continuum are still needed in this population.



**Disclosures.** A. Sena, Gilead: Grant Investigator, Research grant.

**1296. Potential use of Sexually Transmitted Infection (STI) Testing for Expanding HIV Pre-Exposure Prophylaxis (PrEP) at an Urban Hospital Center**

Robert Pitts, MD<sup>1</sup>; Robert Holzman, MD, FIDSA, FSHEA<sup>2</sup>; Richard Greene, MD<sup>3</sup>; Emily Lam, BS<sup>1</sup>; Ellie Carmody, MD, MPH<sup>4</sup> and Scott Braithwaite, MD<sup>5</sup>; <sup>1</sup>Infectious Diseases, New York University, New York, New York, <sup>2</sup>NYU Medical Center, New York, New York, <sup>3</sup>Medicine, New York University, New York, New York, <sup>4</sup>Division of Infectious Diseases and Immunology, New York University School of Medicine, New York, New York, <sup>5</sup>Department of Population Health, New York University, New York, New York

**Session:** 142. HIV: Prevention  
Friday, October 5, 2018: 12:30 PM

**Background.** Despite the high efficacy of PrEP, it continues to be underutilized. We examined the extent to which patients with a documented positive test for STIs were provided PrEP at an urban municipal medical center.

**Methods.** We reviewed data of all patients seen between January 1, 2014 and July 30, 2017 who were > 18 years old and had an initial HIV negative test and ≥1 positive test for Chlamydia, Gonorrhea, or Syphilis. We examined PrEP prescription data by gender, race/ethnicity, and clinic location. Differences between groups were compared using Chi-squared analysis and logistic regression.

**Results.** Of 1,142 initially HIV- patients who were identified as having a positive STI result, 52% were female, 89% either Black or Hispanic, with a median age of 40 years (quartiles 30, 47). 58% had Medicare/Medicaid and 34% were self-pay or uninsured (Table 1). Only 25 (2.1%) of 1,142 patients who had ≥1 STI test positive were prescribed PrEP. No women received PrEP. Whites (aOR: 21.7 [95% CI:4.4, 107, P < 0.001] and Hispanics (aOR:6.64 [95% CI:1.35, 32.8, P = 0.02] were both more likely to receive PrEP than Blacks, after adjusting for age, sex, marital status, and insurance. All PrEP prescriptions originated from the Medicine, Emergency, or HIV specialty clinics although most STI testing was obtained in Emergency and Obstetrical/Gynecological clinics (Table 2).

**Conclusion.** There were significant missed opportunities for HIV prevention among patients with STIs within the medical center, particularly among Hispanic and Black patients. Enrichment programs to educate providers and increase PrEP prescriptions may have a major impact on expanding HIV prevention, especially for women.

**Table 1: Sociodemographics by PrEP Prescriptions Among PrEP Eligible Patients (n = 1,142)**

Age Categories	Prescribed PrEP n=25 n.(%)	Not Prescribed PrEP n=1,117 n.(%)	p-value
18-24	3 (12)	282 (25.2)	0.286
25-34	10 (40)	301 (27)	
35-44	5 (20)	151 (13.5)	
45-54	5 (20)	205 (18.4)	
55+	2 (8)	178 (15.9)	
Sex			
Female	0	591 (53)	<0.001
Race/ Ethnicity			
White	14 (56)	111 (10)	<0.001
Black/ African American	1 (4)	462 (41.2)	
Hispanic or Latino/Latina	10 (40)	544 (48.8)	
Marital Status			
Single	22 (88)	931 (83.4)	0.498
Married	3 (12)	127 (11.3)	
Divorced/Separated/Widowed	0	59 (5.3)	
Insurance			
Public (Medicare/Medicaid)	11 (44)	655 (59)	<0.001
Uninsured	9 (36)	380 (34)	0.048
Private/Commercial	5 (20)	82 (7)	
Positive Gonorrhea test	10 (40)	114 (14.3)	<0.001
Positive Chlamydia test	11 (44)	549 (68.7)	0.009
Positive Syphilis test <sup>†</sup>	11 (44)	505 (53.3)	0.356

<sup>†</sup>Treponemal and/or non-treponemal test

**Table 2: +STIs and PrEP Prescriptions by Location and Gender**

Locations	Patients with +STI	Male +STI Prescribed PrEP (%)	Female +STI Prescribed PrEP (%)
Emergency	358	6 (24)	0
OB/GYN	353	0	0
Medicine	159	15 (60)	0
Psychiatry	111	0	0
Specialty	63	0	0
Not available	37	0	0
Pediatrics	32	0	0
HIV	31	4 (16)	0
Surgery	13	0	0

**Disclosures.** All authors: No reported disclosures.

**1297. Characteristics for PrEP Uptake, Retention, and Discontinuation: Data From the ANCHOR Study**

Poonam Mathur, DO, MPH<sup>1</sup>; Sarah Kattakuzhy, MD<sup>2</sup>; Laura Nussdorf, BS<sup>3</sup>; Kristi Hill, BS<sup>3</sup>; Rachel Silk, BSN, MPH<sup>1</sup>; Chloe Gross, RN, BSN, ACRN<sup>2</sup>; Elizabeth Akoth, RN<sup>2</sup>; Nadeera Sidique, BS<sup>4</sup>; Chloe Chaudhury, BS<sup>3</sup>; David Sternberg, BA<sup>5</sup>; Henry Masur, MD<sup>6</sup>; Shyam Kottlilil, MD, PhD<sup>7</sup> and Elana Rosenthal, MD<sup>2</sup>; <sup>1</sup>Institute of Human Virology, University of Maryland, Baltimore, Maryland, <sup>2</sup>Institute of Human Virology, University of Maryland Division of Infectious Diseases, Baltimore, Maryland, <sup>3</sup>National Institutes of Health, Bethesda, Maryland, <sup>4</sup>Drexel College of Medicine, Philadelphia, Pennsylvania, <sup>5</sup>University of Maryland, College Park, Maryland, <sup>6</sup>Critical Care Medicine Department, National Institutes of Health, Bethesda, Maryland, <sup>7</sup>National Institutes of Health / National Institute of Allergy and Infectious Diseases, Bethesda, Maryland


**Session:** 142. HIV: Prevention  
Friday, October 5, 2018: 12:30 PM

**Background.** People who inject drugs (PWID) have an increased risk for HIV, and HCV infection may foreshadow HIV acquisition in current epidemics. Studies of PWID have demonstrated a desire to obtain HCV treatment; however, use of pre-exposure prophylaxis (PrEP) in this population has not been well studied.

**Methods.** The ANCHOR study is an ongoing single-center study evaluating treatment of HCV in PWID. Enrolled patients have chronic HCV, opioid use disorder, and inject opioids. Patients are treated with sofosbuvir/velpatasvir and offered PrEP. Patients complete baseline community health worker (CHW)-administered surveys, physician assessment of PrEP eligibility, and are offered PrEP uptake.

**Results.** Of 89 enrolled patients, 49 (55%) met CDC criteria for PrEP, and 21 (24%) patients started PrEP. Reasons for not starting PrEP are in Figure 1. Though most patients are black (n = 82, 92.1%) and heterosexual (n = 81, 91%), these patients were less likely to start PrEP (P = 0.0068 and P = 0.0283, respectively). Baseline interest in starting PrEP was correlated with uptake (P = 0.0023), however, self-identifying as high-risk for HIV acquisition or meeting CDC criteria for PrEP were not. Though more patients endorsed sharing of injection equipment to a CHW than a physician (17% vs. 7%), endorsement to a physician rather than CHW was associated with starting PrEP (P = 0.0307). To date, 13 (62%) patients discontinued PrEP, 7 (54%) due to side effects.

**Conclusion.** Preliminary results of the ANCHOR study support that engagement in HCV care provides an opportunity for PWID to participate in PrEP intake; however, we found relatively low uptake in these patients, despite over half meeting CDC criteria. Our findings highlight the importance of counseling by physicians for initiation of PrEP, and suggest that improved communication between CHW and physician regarding risk behaviors could improve uptake. These data also reinforce that patients must be counseled and managed for side effects in order to retain them in care. Given the increasing opioid epidemic in the United States, more consideration needs to be given regarding how to incorporate PrEP into care, and how to effectively target and improve interest in PrEP for high-risk populations with poor uptake, including minorities and PWID.



**Disclosures.** C. Gross, Merck, Pfizer, Johnson and Johnson: Shareholder, stock. E. Rosenthal, Gilead Sciences, Merck: Grant Investigator, Grant recipient.

**1298. Acquisition of TDF-Susceptible HIV Despite High Level Adherence to Daily TDF/FTC PrEP as Measured by Dried Blood Spot (DBS) and Segmental Hair Analysis: A Case Report**

Stephanie E. Cohen, MD, MPH<sup>1</sup>; Darpun Sachdev, MD<sup>1</sup>; Sulggi Lee, MD, PhD<sup>2</sup>; Susan Scheer, PhD MPH<sup>3</sup>; Oliver Bacon, MD, MPH<sup>1</sup>; Miao-Jung Chen, PhD, MPH<sup>3</sup>; Clarissa Ospina Norvell, FNP<sup>2</sup>; Hideaki Okochi, PhD<sup>4</sup>; Peter Anderson, PharmD<sup>5</sup>; Susa Coffey, MD<sup>2</sup>; Hyman Scott, MD<sup>2,6</sup>; Diane Havlir, MD, FIDSA<sup>2</sup> and Monica Gandhi, MD, MPH<sup>7</sup>; <sup>1</sup>Disease Prevention and Control Branch, San Francisco Department of Public Health, San Francisco, California, <sup>2</sup>Division of HIV, Infectious Diseases and Global Medicine, UCSF, San Francisco, California, <sup>3</sup>HIV Epidemiology Section, San Francisco Department of Public Health, San Francisco, California, <sup>4</sup>Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, UCSF, San Francisco, California, <sup>5</sup>University of Colorado Anschutz Medical Campus, Aurora, Colorado, <sup>6</sup>Bridge HIV, San Francisco Department of Public Health, San Francisco, California, <sup>7</sup>Medicine, Division of HIV, Infectious Diseases and Global Medicine, UCSF, San Francisco, California

**Session:** 142. HIV: Prevention  
*Friday, October 5, 2018: 12:30 PM*

**Background.** Pre-exposure prophylaxis (PrEP) with emtricitabine/tenofovir (TFV) disoproxil fumarate (FTC/TDF) is highly protective against HIV infection. We report the second case of acquisition of TDF-susceptible HIV despite high adherence to PrEP, confirmed by drug level testing.

**Methods.** PrEP adherence was assessed by measuring FTC/TDF metabolites in dried blood spots (DBS) and FTC/TFV concentrations in segments of scalp hair. Genotypic and phenotypic resistance were evaluated. HIV partner services (PS) and HIV sequences reported to HIV surveillance with a genetic distance  $\leq 1.5\%$  (by HIV-Trace) identified likely transmission partners.

**Results.** A 21-year-old Latino man presented 13 months after PrEP initiation. He was HIV negative by rapid HIV antibody (Ab) and HIV RNA pooling (detection limit ~40 copies/mL) at PrEP initiation and at months 3, 6, and 10. At the 13-month visit, he was asymptomatic and his rapid HIV Ab was negative. Five days later, his HIV RNA was reported as positive (559 copies/mL). He was notified of the result, linked to care and immediately started antiretroviral treatment (ART), at which point his RNA was 1544 copies/mL and his HIV Ab test was positive. The HIV genotype had M184V, L74V and K103N mutations and phenotypic susceptibility to TDF. TFV/FTC levels by LC-MS/MS measured in 1 cm segments of hair collected at ART initiation indicated consistently high PrEP adherence in each of the preceding 6 months. TFV-diphosphate and FTC-triphosphate levels in DBS collected 2 days after ART initiation were 1012 fmol/punch and 0.266 pmol/punch, confirming high adherence over the preceding 6 weeks. Between PrEP initiation and HIV acquisition, he had 1 episode of urethral chlamydia and three episodes of urethral gonorrhea. The likely transmission partner, named during PS, had no history of viral suppression in HIV surveillance and harbored the same resistance mutations, with a genetic distance between the two patients of 0.66%. The partner was re-linked to care and had a current HIV RNA of 15,130 copies/mL.

**Conclusion.** Acquisition of TDF-susceptible HIV infection can occur despite high PrEP adherence. Quarterly HIV and STD screening of patients on PrEP, combined with prompt linkage to care and PS for those diagnosed with HIV, facilitates early diagnosis and prevents further transmission of HIV.

**Disclosures.** S. E. Cohen, Gilead: Investigator in PrEP study for which Gilead donated drug, donated study drug and paid for drug testing during the PrEP demo project, of which I was a co-PI (the study has ended). S. Lee, Viiv Healthcare: Investigator, Research grant. Gilead Sciences: Investigator, Research grant. P. Anderson, Gilead: Consultant and Investigator, funds were paid to the institution for contract work and grant support and Research support. D. Havlir, Gilead: Investigator, Gilead Sciences provides antiretroviral therapy for a NIH funded study that she is conducting and Research support.

**1299. Iowa TelePrEP: Preliminary Experience with a Public Health-Partnered, Telemedical PrEP Delivery Model in a Rural State**

Angela Hoth, PharmD MPH<sup>1</sup>; Cody Shafer, EIS/PrEP Coordinator<sup>2</sup>; Dena Dillon, PharmD AAHIVP<sup>3</sup>; Constanza Schetz, Health Educator<sup>4</sup>; Seth Owens, Health Educator<sup>4</sup>; Kathryn Edel, Health Educator<sup>4</sup> and Michael Ohl, MD MSPH<sup>5</sup>; <sup>1</sup>Division of Infectious Diseases, Department of Internal Medicine, University of Iowa Health Care, Iowa City, Iowa, <sup>2</sup>Bureau of HIV, STD, and Hepatitis, Iowa Department of Public Health, Des Moines, Iowa, <sup>3</sup>Pharmaceutical Care, University of Iowa Department of Pharmaceutical Care, Iowa City, Iowa, <sup>4</sup>Johnson County Public Health Department, Iowa City, Iowa, <sup>5</sup>Division of Infectious Diseases, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa

**Session:** 142. HIV: Prevention  
*Friday, October 5, 2018: 12:30 PM*

**Background.** Access to HIV pre-exposure prophylaxis (PrEP) is often poor in small urban and rural areas due to long distances to PrEP providers and stigma. In 2017, the Iowa Department of Public Health (IDPH), University of Iowa (UI), and community representatives collaborated to develop a public health-partnered telemedical PrEP delivery model to overcome these barriers (TelePrEP). IDPH personnel working in five sexually transmitted infection (STI) clinics and partner services (PS) programs in Eastern Iowa screened clients for PrEP indications and referred those with need to TelePrEP pharmacist providers at UI. Via collaborative practice, pharmacists completed initial and follow-up PrEP home video visits with clients on smart phones and laptops. Clients obtained laboratory monitoring and STI screening in public health-affiliated and local laboratories in accordance with USPHS/CDC guidelines,

and received PrEP medication by mail. PS personnel linked TelePrEP clients with newly-identified STIs to local treatment.

**Methods.** Using the PrEP continuum as framework, we used IDPH databases and UI medical records to conduct a retrospective process evaluation of the TelePrEP model (February 2017–April 2018).

**Results.** TelePrEP received 44 referrals from public health and 59 self-referrals via advertising. Pharmacists completed 84 initial visits (81% of referrals), including 37 visits (84%) with clients referred by public health. Most (94%) started emtricitabine/tenofovir after initial visits. Retention in TelePrEP at 6 months was 87%. 96% of guideline-indicated laboratory tests (HIV, creatinine, STI, hepatitis) were completed at baseline and follow-up. Rates of extragenital chlamydia and gonorrhea screening were lower (74 of 104 completed screens) due to variable availability of swabs at local laboratories. 15 clients were diagnosed with 20 STIs on screening (6 syphilis, four gonorrhea, 10 chlamydia) and one unrecognized pregnancy was identified. PS linked all clients with STIs on screens to treatment within 14 days (80% in 3 days).

**Conclusion.** Using telemedicine, healthcare systems can partner with public health administered STI clinics and PS programs to create virtual PrEP delivery models in rural settings. Public health partnerships enhance client identification and ensure linkage to care for new STI diagnoses in telemedicine programs.

**Disclosures.** A. Hoth, Gilead Sciences, Inc.: Research team member, Research support. M. Ohl, Gilead Sciences, Inc.: Grant Investigator, Research grant.

**1300. Young Heterosexual Men in Rural South Africa Want Access to PrEP**

Alisse Hannaford, BS<sup>1,2,3</sup>; Bulelani Khoza, NSC<sup>4</sup>; Anthony P Moll, MBChB<sup>4</sup> and Sheela V Shenoi, MD, MPH<sup>2</sup>; <sup>1</sup>Icahn School of Medicine at Mount Sinai, New York City, New York, <sup>2</sup>Yale University School of Medicine, New Haven, Connecticut, <sup>3</sup>Doris Duke Charitable Foundation, New Haven, Connecticut, <sup>4</sup>Church of Scotland Hospital, Tugela Ferry, KwaZulu-Natal, South Africa

**Session:** 142. HIV: Prevention  
*Friday, October 5, 2018: 12:30 PM*

**Background.** While many HIV prevention services in South Africa specifically support women and girls, substantial gaps exist in HIV prevention, testing and treatment services targeting men and boys. We aimed to characterize HIV prevention knowledge, sexual-risk behaviors and interest in HIV pre-exposure prophylaxis (PrEP) among young men in rural KwaZulu-Natal.

**Methods.** Men were identified at community settings such as taverns, fast-food restaurants, and local stores. Interviews were conducted confidentially and anonymously in Zulu, and were recorded, translated and transcribed. Transcripts were coded to identify themes.

**Results.** Thirty-one HIV negative men (median age 26, IQR 23–31) were interviewed, 52% with a history of STI and 77% unemployed. While most (61%) perceived themselves to be at risk for HIV, less than half had tested for HIV in the prior 3 months (36%), the majority reported inconsistent condom use (87%), and most reported partners outside their relationship (84%). While only a quarter had previously heard of PrEP, all were interested in initiating. Four participants felt PrEP should only be for men because polygamy is acceptable. While most men wanted their partners on PrEP (77%), they also felt that their female partners initiating PrEP would signify a lack of trust in the relationship, while paradoxically acknowledging that their own multiple sexual relationships put their partner at risk. Men expressed fear of destabilizing new relationships by asking about HIV status, and admitted being less likely to discuss HIV status and condoms during sexual encounters involving alcohol. Men felt that using PrEP might lead to decreased condom use and enable their female partners to be sexually active with other men. Men were concerned that if they initiated PrEP they would be mistaken as HIV positive.

**Conclusion.** Men in heterosexual relationships in rural South Africa acknowledge engaging in high HIV risk behaviors and feel that they should have access to PrEP. They report contradictory perspectives about their female partners accessing PrEP, and are concerned about PrEP increasing HIV risk behaviors, which needs further exploration. Heterosexual men in sub-Saharan Africa should be targeted for combination HIV prevention services, including PrEP.

**Disclosures.** S. V. Shenoi, Amgen Pharmaceuticals: Spouse does part-time contract work, Salary.

**1301. Evaluation of the Rates of HIV Post-Exposure Prophylaxis Completion After the Implementation of an Automated Referral System in the Emergency Department**

Erika Reategui Schwarz, MD<sup>1</sup>; Madeleine Gysi, MD<sup>1</sup>; Finn Schubert, MPH<sup>2</sup> and Fanny Ita-Nagy, MD<sup>3</sup>; <sup>1</sup>Internal Medicine, NYU Langone Hospital-Brooklyn, Brooklyn, New York, <sup>2</sup>Clinical Research, NYU Langone Hospital-Brooklyn, Brooklyn, New York, <sup>3</sup>Infectious Diseases and Immunology, NYU Langone Hospital-Brooklyn, Brooklyn, New York

**Session:** 142. HIV: Prevention  
*Friday, October 5, 2018: 12:30 PM*

**Background.** A 28-day regimen of Post-Exposure Prophylaxis (PEP) administered within 72 hours significantly reduces HIV infection, for both occupational and nonoccupational exposures (NOE); however, adherence to PEP for NOE has been reported to have poor rates of completion.<sup>1</sup> To optimize PEP referrals from our ED to our clinics, we implemented an automated referral system to maximize PEP completion and link patients to outpatient care and HIV pre-exposure prophylaxis (PrEP), if appropriate.